Developing universal AAV immuno-gene therapy for oncology

Traditional limits to the application of AAV-driven gene therapy are increasingly being eliminated. David McCall, Senior Editor, BioInsights, speaks to Nicole Paulk, CEO & Founder of Siren Biotechnology, about her team’s work in creating both the world’s first AAV-based immunotherapy in the oncology space, and the first universal AAV gene therapy product that can be used to treat multiple indications.

Please enter your email to access content Read now